Compare Docusign Inc (DOCU) vs Medpace Holdings Inc (MEDP) Price & Performance

DOCU trades at $57.89, down 2.93% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.09 exceeding expectations. Revenue growth remains steady, reaching $2.98B in 2025, while profitability improved significantly with a net income margin of 35.87%.

The outlook is mixed with solid fundamentals supporting long-term growth, but valuation multiples appear elevated. Key risks include competitive pressures and market volatility. Analyst consensus is cautious with a $55.40 price target below current levels, suggesting limited near-term upside despite positive operational trends.

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.